Neurolens, a medical device company focused on vision care, received $45 million in venture debt funding from Trinity Capital, Trinity managing director Igor DaCruz tells Axios exclusively.
Why it matters: Eye care has lagged behind other health fields in terms of technological advancement, but the sector is undergoing a much-needed modernization.
